Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bisthianostat - Shanghai Theorion Pharmaceutical

Next Previous
Drug Profile

Bisthianostat - Shanghai Theorion Pharmaceutical

Alternative Names: bisthiazol-based pan-HDAC - Shanghai Theorion Pharmaceutical; CF367; CF367-C; CFH-367-C; PY-1

Latest Information Update: 28 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Institute of Materia Medica
  • Developer Shanghai Institute of Materia Medica; Shanghai Theorion Pharmaceutical
  • Class Amides; Antineoplastics; Cyclopropanes; Small molecules; Thiazoles
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Multiple myeloma

Most Recent Events

  • 28 Jul 2023 No recent reports of development identified for phase-I development in Multiple-myeloma(Late-stage disease, Recurrent, Second-line therapy or greater) in China (PO)
  • 31 Jul 2021 Bisthianostat is still in phase I trials for Multiple myeloma in China (NCT03618602)
  • 09 Jun 2021 Efficacy, pharmacokinetic and adverse events data from a phase I trial in Bisthianostat presented at the 26th Congress of the European Haematology Association (EHA-2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top